Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$19.68
$11.48
$19.75
$384.69M1.35129,776 shs8,375 shs
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$4.35
$1.10
$43.35
$2.55M1.83103,866 shs137,800 shs
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$0.35
$0.03
$3.17
$3.50M0.497.01 million shs61.02 million shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
$1.48
$1.65
$0.82
$3.88
$58.11M1.95494,777 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00%0.00%0.00%0.00%0.00%
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
0.00%0.00%0.00%0.00%-94.36%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/AN/AN/AN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.8472 of 5 stars
0.00.00.04.70.62.50.0
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00
N/AN/AN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00
N/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
2.50
Moderate Buy$2.17∞ Upside
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$340K0.00N/AN/A$2.89 per share0.00
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$15.77M0.00N/AN/A$37.68 per share0.00
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$496K0.00N/AN/A$0.54 per share0.00
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/A$2.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/A
0.47
0.47
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/A
3.31
3.24
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
1.83
2.54
2.54
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/A
2.96
2.96
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
21719.48 millionN/AOptionable
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
561.48 million1.42 millionOptionable
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
190108.57 million111.84 millionOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
13739.26 million29.44 millionNot Optionable

Recent News About These Companies

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
TCR2 Therapeutics Insider Trades Send a Signal
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
Mizuho Downgrades Tcr2 Therapeutics (TCRR)
4 Analysts Have This to Say About TCR2 Therapeutics
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

Top Headlines

View All Headlines
Cellular Biomedicine Group stock logo

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Eiger BioPharmaceuticals stock logo

Eiger BioPharmaceuticals NASDAQ:EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Gritstone bio stock logo

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

TCR2 Therapeutics stock logo

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.